News
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single ... with low-grade intermediate risk non-muscle invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback